• Diabetic kidney disease is the leading cause of kidney failure worldwide.
• Chronic, sub-clinical, non-resolving inflammation contributes to the pathophysiology of renal and cardiovascular disease associated with diabetes.
• Targeting chronic inflammation may offer a route to novel therapeutics for diabetic kidney disease. 

The five-compartment model of impairment due to chronic inflammation in diabetic kidney disease

• Evidence has shown that sub0clinical chronic inflammation plays a key role in the development and progression of DKD.
• The precision medicine approach has the potential to improve positive health outcomes while reducing unnecessary side effects and costs, but it needs a considerably improved understanding of diabetic kidney disease.
• The five-compartment model aims to inform the selection of pre-clinical models to identify and validate candidates for clinical testing and for designing clinical trials with selection criteria and efficacy assessments providing early evidence of clinical benefits in patients with diabetic kidney disease. 

Reference

Hofherr A, Williams J, Gan L-M, Soderberg M, et al. Targeting inflammation for the treatment of diabetic kidney disease: a five-compartment mechanistic model. BMC Nephrology. 2022; Article number: 208.